| Literature DB >> 30921421 |
Hassen Mohammed1,2, Mark McMillan1,2, Claire T Roberts1, Helen S Marshall1,2,3.
Abstract
BACKGROUND: Maternal pertussis vaccination has been introduced in several countries to prevent pertussis morbidity and mortality in infants too young to be vaccinated. Our review aimed to systematically collect and summarize the available evidence on the effectiveness of interventions used to improve pertussis vaccination uptake in pregnant women.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30921421 PMCID: PMC6438510 DOI: 10.1371/journal.pone.0214538
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The inclusion and exclusion criteria used during the screening process.
| Criteria | Included |
|---|---|
| Study design | Studies comparing pertussis vaccine uptake among pregnant women who were exposed to an intervention vs. standard care Observational studies Randomised controlled trials Interventions that include pertussis as a compound of the immunization i.e. Tdap or Tdap-IPV |
| Population | Pregnant women |
| Outcomes | Pertussis vaccination uptake during pregnancy |
| Publication date | Up to January 2019 |
| Language | Studies published in English |
Fig 1Flow diagram of the process and results of study selection.
Strategies used to improve pertussis vaccination uptake among pregnant women.
| Included studies | Interventions for health care providers | Pregnant women focussed intervention | Interventions to enhance vaccination access | ||||
|---|---|---|---|---|---|---|---|
| Provider reminder/recall | Provider Education | Standing orders | Provider feedback | Pregnant women education | Extend service location | Increase stock | |
| Kriss [ | √ | ||||||
| Payakachat [ | √ | ||||||
| Chamberlain [ | √ | √ | √ | √ | √ | ||
| Morgan [ | √ | √ | |||||
| Healey [ | √ | √ | √ | ||||
| Mohammed [ | √ | √ | √ | √ | |||
Fig 2Risk of bias in included RCT studies.
Absolute benefit increase and 95% confidence intervals of each intervention.
| Author | Study design, period and methods | Participants and setting | Uptake of maternal Tdap vaccine (n, %) | Absolute benefit increase, ABI (95% CI) | Confounders adjusted for |
|---|---|---|---|---|---|
| Academic medical centre Arkansas, USA | None | ||||
| May–August 2014 | 65/144 (45%) | ||||
| Vaccine information statement (sVIS) | |||||
| 66/135 (49%) | |||||
| Plain language version (mVIS) | |||||
| Pregnant African American women in 4 antenatal clinics in metropolitan Atlanta, USA | None | ||||
| January 30-April 3, 2013. | 2/34 (6%)during pregnancy | ||||
| Follow up: after delivery | 4/34 (12%) postpartum | ||||
| Routine prenatal care | 2/31 (6%) during pregnancy | ||||
| 7/31 (23%) Postpartum | |||||
| 1. Messaging video | |||||
| 2. Messaging iBook | 2/30 (7%) during pregnancy | ||||
| 13/30 (43%) postpartum | |||||
| Pregnant women from Parkland Hospital, USA | None | ||||
| 5,064/10,600 (48%) | |||||
| 9,879/10,201 (97%) | |||||
| Women delivering at Texas Children’s Hospital, USA | None | ||||
| (36%) | |||||
| (61%) | |||||
| N = 6577 | |||||
| Pregnant women attending a territory obstetric hospital in Adelaide, Australia | Age, parity, country of birth, provider recommendation | ||||
| 5/25 (20%) | |||||
| November 2014 and July 2016 | |||||
| 140/155 (90%) | |||||
| Pregnant women from obstetric practices in Georgia, USA | Adjusted for clustered study design and intention to receive the vaccine before delivery | ||||
| December 2012–April 2013 | 13/151 (9%) | ||||
| 19/140 (14%) | |||||
a The authors did not state the number of vaccinated women pre-and post-intervention